SCHEMBL9423932

SCHEMBL9423932

CCCCCC1(N)C=CC=CC1C=O

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29210938 0.78 POLA1 (0.43) POLA1
SCHEMBL3102574 0.75 POLA1 (0.35) POLA1
SCHEMBL31070849 0.70 POLA1 (0.30) POLA1
SCHEMBL3431677 0.69
SCHEMBL2033847 0.69
SCHEMBL3458780 0.67 KCNH2 (0.39)
SCHEMBL9187292 0.65
SCHEMBL4240527 0.63
SCHEMBL3650233 0.62
SCHEMBL11528752 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5318971-A Also antihyperproliferative skin disease agents, e.g. psoriaisis; side effect reduction SCHERING CORPORATION (US) 1994-06-07 US disclosed
US-5064837-A Antiallergens SCHERING CORPORATION (US) 1991-11-12 US disclosed
WO-1991007401-A1 3-SUBSTITUTED-1-(ARYL OR ARYLALKYL)-2(1H)-QUINOLINONES SCHERING CORPORATION (US) 1991-05-30 WO disclosed